Respiratory Failure and Long Sars-Cov-2 in a Patient with Progressive Multiple Sclerosis on Immunosuppressive Therapy

The world, and especially our healthcare system, is currently confronted with one of the greatest challenges of modern times. At June 2021, the SARS-CoV-2 pandemic has already infected more than 174 million people worldwide and resulted in 3,7 million deaths. A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the use of immunosuppressive therapies for the treatment of Multiple Sclerosis due to an increased risk of contracting SARS-CoV-2 and more severe disease. Multiple Sclerosis is known as an autoimmune disease, in which the immune system — which normally protects against viruses and other insults — wrongly attacks the fatty sheath around nerve fibers to disrupt the flow of electric signals, causing a variety of symptoms. Most Multiple Sclerosis disease-modifying therapies are designed to suppress these attacks by limiting immune responses. But that can leave people more vulnerable to infections, including SARS-CoV-2. Actually the large number of different disease-modifying therapies in the treatment of neuroimmunological diseases such as multiple sclerosis poses a challenge. We report a case of Respiratory Failure and Sars-Cov-2 in a Patient with Progressive multiple sclerosis on immunosuppressive therapy.

Real Time Impact Factor: Pending

Author Name:


Keywords: Progressive Multiple Sclerosis; Long Sars-Cov-2; Respiratory Failure

ISSN: ISSN 2652-4449


EOI/DOI: 10.53634/2652-4449.100028

Add Citation Views: 1


Advance Search

Get Eoi for your journal/conference/thesis paper.

Note: Get EOI for Journal/Conference/ Thesis paper.


Share With Us

Directory Indexing of International Research Journals